Toyama, Japan
Toyama, Japan

The University of Toyama is a Japanese national university in Toyama Prefecture established in 1949. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
University of Electro - Communications, Kikuchi Seisakusho Co., University of Toyama and Tss Co. | Date: 2015-09-28

An orthosis 1 includes: an outer layer 2 which maintains a substantially elliptic shape; and a buffer 3 provided on the inner periphery of the outer layer 2, and buffers predetermined sites on the head. When the orthosis 1 is worn deviating from a state where the minor axis of the substantially elliptic shape corresponds to the width of the head, pressers 24a, 24b are formed which press the predetermined sites on the head with a stronger force than a force before deviation. The outer layer 2 includes adjustment portions 23a and 23b which can be close or apart in the minor axis direction of the substantially elliptic shape. The orthosis 1 further includes an adjuster 4 which adjusts the adjustment portions 23a, 23b so that the length of the minor axis of the substantially elliptic shape can correspond to the width of the head.


Patent
University of Electro - Communications, Kikuchi Seisakusho Co., University of Toyama and TSS Co. | Date: 2017-08-09

An orthosis is adjustable to the head size of a wearer, and induces a rotational movement of the head. The orthosis 1 includes: an outer layer 2 which maintains a substantially elliptic shape; and a buffer 3 provided on the inner periphery of the outer layer 2, and buffers predetermined sites on the head. When the orthosis 1 is worn deviating from a state where the minor axis of the substantially elliptic shape corresponds to the width of the head, pressers 24a, 24b are formed which press the predetermined sites on the head with a stronger force than a force before deviation. The outer layer 2 includes adjustment portions 23a and 23b which can be close or apart in the minor axis direction of the substantially elliptic shape. The orthosis 1 further includes an adjuster 4 which adjusts the adjustment portions 23a, 23b so that the length of the minor axis of the substantially elliptic shape can correspond to the width of the head.


Patent
University of Toyama, Kracie Pharma Ltd., National Cancer Center and Tokyo University of Science | Date: 2015-04-10

The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.


Patent
University of Toyama | Date: 2016-12-07

The purpose of the invention is to provide means with which it is possible to efficiently select a vector to which a foreign gene has been introduced when a foreign gene is to be introduced by homologous recombination to a vector having multiple sequences homologous with one another. The vector comprises, in succession, a replication origin, a sequence A, a marker gene X, two sequences C and D for introducing a foreign gene by homologous recombination, and a sequence B homologous with sequence A. The two sequences C and D are directly or indirectly adjacent to one another. The vector is used for introducing a foreign gene between the two adjacent sequences C and D.


Patent
University of Toyama and Science World Inc. | Date: 2017-05-10

As a method for highly efficiently amplifying a TCR cDNA in a short period of time, there is provided a method for amplifying a T cell receptor (TCR) cDNA, which comprises the following step (1) and step (2):(1) the step of performing PCR by using at least one kind of the L primer mentioned below, the C primer 1 or UTR primer 1 mentioned below, and cDNA obtained from a single cell as the template to obtain an amplification product 1;- an L primer of 30- to 60-nucleotide length comprising an adapter part of 15- to 25-nucleotide length, and a leader region-annealing part of 15- to 25-nucleotide length, which is ligated downstream from the adapter part, and can anneal to a part of a leader region containing a translation initiation codon, or an upstream part thereof,- a C primer 1 of 15- to 25-nucleotide length, which can anneal to a part of a constant region, or a UTR primer 1 of 15- to 25-nucleotide length, which can anneal to a part of a 3 untranslated region;(2) the step of performing PCR by using the adaptor primer mentioned below, the C primer 2 or UTR primer 2 mentioned below, and the amplification product 1 as the template to obtain an amplification product 2;- an adapter primer of 15- to 25-nucleotide length, which can anneal to the adapter part of the amplification product 1,- a C primer 2 of 15- to 25-nucleotide length, which can anneal to a part of the constant region existing upstream from the region to which the C primer 1 anneals, or a UTR primer 2 of 15- to 25-nucleotide length, which can anneal to a part of the 3 untranslated region existing upstream from the region to which the UTR primer 1 anneals.


Sakurai H.,University of Toyama
Trends in Pharmacological Sciences | Year: 2012

The transcription factors nuclear factor-κB (NF-κB) and activating protein-1 (AP-1) are critical regulators of stress responses, immunity, inflammation and cancer. A large variety of cellular stimuli utilize these signaling pathways through a common upstream kinase transforming growth factor-β-activated kinase 1 (TAK1). TAK1 was originally identified as a mitogen-activated kinase kinase kinase (MAP3K) activated by transforming growth factor-β (TGF-β); however, it has been characterized as a key regulator in inflammatory and immune signaling pathways. In addition, microbial proteins and components of host cell signaling scramble for the TAK1 complex in innate immunity. This review highlights the recent advances in the activation mechanisms and physiological functions of TAK1. Research targeting TAK1 raises the potential for new therapeutic options for inflammatory disorders, including cancer. © 2012 Elsevier Ltd.


Patent
University of Toyama and Ahresty Corporation | Date: 2016-04-07

An AlMgSi-based aluminum alloy includes 0.015 to 0.12 mass % of Sr, the aluminum alloy producing a cast metal structure in which Mg_(2)Si is crystallized in a fine agglomerate form.


Inobe T.,University of Toyama | Matouschek A.,University of Texas at Austin
Current Opinion in Structural Biology | Year: 2014

The proteasome is the main proteolytic machine in the cytosol and nucleus of eukaryotic cells where it degrades hundreds of regulatory proteins, removes damaged proteins, and produces peptides that are presented by MHC complexes. New structures of the proteasome particle show how its subunits are arranged and provide insights into how the proteasome is regulated. Proteins are targeted to the proteasome by tags composed of several ubiquitin moieties. The structure of the tags tunes the order in which proteins are degraded. The proteasome itself edits the ubiquitin tags and drugs that interfere in this process can enhance the clearance of toxic proteins from cells. Finally, the proteasome initiates degradation at unstructured regions within its substrates and this step contributes to substrate selection. © 2014 Elsevier Ltd.


Patent
University of Toyama and Fushimi Pharmaceutical Co. | Date: 2016-03-02

A collagen production promoter in cells, containing at least one member selected from the group consisting of 1,5-anhydro-D-glucitol and derivatives thereof; and a composition containing the collagen production promoter. Since the collagen production promoter containing 1,5-AG or derivatives thereof of the present invention is suitably used as cosmetics, medicinal formulations, foods, and the like, for promoting collagen production in cells, for example, preventing and/or improving wrinkles of skin.


Patent
University of Toyama | Date: 2015-01-14

An object of the present invention is to stimulate a T cell without using a peptide/MHC tetramer. In the present invention, the step of supplying an antigen peptide to a T cell having a T cell receptor (TCR) that can recognize the antigen peptide on cell surface to form a complex of a major histocompatibility complex (MHC) molecule on the cell surface of the T cell and the antigen peptide is used, and the T cell is stimulated through recognition by TCR of the antigen peptide as the MHC molecule-antigen peptide complex on the cell surface of the same T cell. Such a stimulating and activating method would be applicable to not only T cells, but also various cells. According to the present invention, an antigen-specific T cell can be identified without establishing any antigen-specific T cell strain, and without using such a reagent as MHC/peptide tetramer. That is, a cancer-specific T cell can be efficiently and conveniently identified.

Loading University of Toyama collaborators
Loading University of Toyama collaborators